The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
MEDTECH Reports Revenue Growth of 81% to €3.1 Million for Fiscal Third Quarter 2015/16
Apr. 08, 2016 10:42AM PST
Medical Device InvestingMEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing surgical robots, has today announced its revenue for the fiscal third quarter of 2016 (3 months ended March 31, 2016). According to the news: Steady growth momentum throughout Q3 During the 3rd quarter of the 2015/16 fiscal period, Medtech continued to expand …
MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing surgical robots, has today announced its revenue for the fiscal third quarter of 2016 (3 months ended March 31, 2016).
According to the news:
Steady growth momentum throughout Q3
During the 3rd quarter of the 2015/16 fiscal period, Medtech continued to expand with steady progress in revenue of €3.1 million, up 81% compared with the same period in the prior year. With the sale of 10 new ROSA™ systems during the quarter (7 in the United States, 2 in China and 1 in France), Medtech has pursued its strategy to increase market share. Furthermore, this quarter Medtech recorded the first sale of its ROSA™ Spine robot in the United States, following FDA clearance in January 2016.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.